Biotechnology company Artiva Biotherapeutics (ARTV.US) priced its IPO at $12/share and is set to list on the Nasdaq tonight.
AInvestFriday, Jul 19, 2024 9:10 am ET
1min read

Biotechnology company Artiva Biotherapeutics (ARTV.US), which focuses on developing NK cell-based treatments for patients with autoimmune diseases and cancer, announced the terms of its IPO, which consists of 1.39 million shares priced at $12 per share, raising $16.7 million. The price range was lower than the previous guidance of $14 to $16 per share, but the number of shares was higher than the previous guidance of 870,000 shares. Artiva Biotherapeutics is scheduled to begin trading on the Nasdaq on July 19, 2018, under the ticker symbol ARTV.

As part of the offering, Artiva also granted the underwriters a 30-day option to purchase up to an additional 20.88 million shares of common stock at the IPO price (net of underwriting discounts and commissions).

Artiva focuses on developing NK cell-based treatments for patients with autoimmune diseases and cancer. Its lead candidate, AlloNK, is currently in a Phase 1b clinical trial for lupus nephritis and is also in a multi-system autoimmune disease trial launched by a consortium of researchers. Artiva expects to report preliminary data from at least one trial by the first half of 2019.

The offering is expected to close on July 22, 2018.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.